|
NCI Extramural Support
|
Extramural Support
|
$13,000
|
$13,000
|
NA
|
NCI (NCI)
|
|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
$130,402
|
N/A
|
National Institutes of Health
|
|
Frameshift peptide vaccine for the prevention Lynch syndrome-associated gastrointestinal cancer HHSN2612015000391 TORFP: 2018-E12 POP: 9/17/2018 to 3/16/2021
|
261201500039I
|
$894,832
|
|
-, -
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
Topic 371 - Phase I SBIR Contract - Valudation and Optimization of RP-185 as Adjuvant to Exploit the Immune Response Generated by Radiation
|
261201800023C
|
$299,847
|
|
-, -
|
RIPTIDE BIOSCIENCE, INC.
|
|
Topic 374 - Phase I - Targeted and Sustained Release Microparticles for Colon Cancer Chemoprevention
|
261201800035C
|
$299,810
|
|
-, -
|
ZYMERON CORPORATION
|
|
IGF::OT::IGF
|
261201800038C
|
$1,499,993
|
|
-, -
|
INTELLIGENT AUTOMATION, INC.
|
|
IGF::OT::IGF
|
261201800047C
|
$1,499,914
|
|
-, -
|
CHARLES RIVER ANALYTICS, INC.
|
|
NATIONAL LONGITUDINAL MORTALITY STUDY (NLMS) AGREEMENT W/ CENSUS & DCCPS/DCEG
|
APC18001-001
|
$55,000
|
|
-, -
|
CENSUS, UNITED STATES BUREAU O
|
|
NCHS SMALL AREA EST
|
APC18002-001
|
$50,000
|
|
-, -
|
CENTERS FOR DISEASE CONTROL &
|
|
NATIONAL CONFERENCE ON TOBACCO OR HEALTH
|
APC18003-001
|
$750
|
|
-, -
|
CENTERS FOR DISEASE CONTROL &
|
|
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
|
3UM1CA186704-04S1
|
$170,500
|
|
ABBRUZZESE, JAMES
|
DUKE UNIVERSITY
|
|
Postmenopausal women's alcohol study
|
ZIA CP000101 10336
|
$951
|
|
Abnet, Christian
|
DCEG (NCI)
|
|
Frederick repository and lab support
|
ZIA CP000112 10313
|
$61,784
|
|
Abnet, Christian
|
DCEG (NCI)
|
|
Gastric and Esophageal Malignancies in Northern Iran (GEMINI): Case-Control Study
|
ZIA CP000185 10318
|
$63,563
|
|
Abnet, Christian
|
DCEG (NCI)
|
|
The Golestan Cohort Study
|
ZIA CP000185 10361
|
$65,336
|
|
Abnet, Christian
|
DCEG (NCI)
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-10
|
$461,172
|
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Sphingolipid Signaling in Mammals
|
ZIA BC 011187
|
$679,649
|
|
Acharya, Jairaj
|
CCR (NCI)
|
|
Li-Fraumeni Syndrome in Brazil
|
ZIA CP010144 10769
|
$53,072
|
|
Achatz, Maria Isabel
|
DCEG (NCI)
|
|
Washington University Small Animal Imaging Resource
|
5U24CA083060-09
|
$645,635
|
$32,282
|
ACKERMAN, JOSEPH
|
WASHINGTON UNIVERSITY
|
|
Identifying molecular drivers of tumor heterogeneity in pancreatic cancer
|
1F31CA224792-01A1
|
$36,672
|
|
ADAMS, CHRISTINA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Children's Oncology Group Phase 1 / Pilot Consortium
|
2U01CA097452-06
|
$2,573,434
|
$1,441,123
|
ADAMSON, PETER
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
$507,804
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-08
|
$1,347,488
|
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
Genetics of Graft-versus-Host Disease
|
1R01CA231141-01
|
$265,229
|
|
AFSHAR-KHARGHAN, VAHID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Functional analysis of signaling to and from p53 in ca
|
5R01CA098916-06
|
$258,227
|
$25,823
|
AGARWAL, Munna
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
$14,536
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systems
|
1R01CA227136-01A1
|
$454,956
|
$454,956
|
AGHI, MANISH
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Clinical study of AdV-tk radiogenetherapy for malignant*
|
4R44CA107745-03
|
$788,188
|
$788,188
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-10S1
|
$54,859
|
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-10S2
|
$188,884
|
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy
|
1R43CA228813-01A1
|
$300,000
|
|
AHMED, HAFIZ
|
GLYCOMANTRA, INC.
|
|
Studies of Occupational Cancer (Pesticides)
|
Z01 CP010119
|
$1,978,544
|
$23,836
|
Alavanja
|
DCEG (NCI)
|
|
ATBC Study
|
ZIA CP010195 03031
|
$738,165
|
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
Study of Weight Change in Breast Cancer Patients Receiving Adjuvant Chemotherapy
|
ZIA CP010197 10350
|
$15,920
|
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
Cancer Prevention and Control Health Disparities Training Program
|
5T32CA078447-18
|
$161,530
|
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
Cancer Information Service
|
N02CO511003-003
|
$933,772
|
$17,742
|
ALBRECHT, TERRANCE
|
Wayne State University
|
|
Chemically produced neural progenitors loaded with ferumoxide-protamine sulfate complex for visualization of gliomas
|
1R43CA228726-01A1
|
$300,000
|
$300,000
|
ALEXANIAN, ARSHAK
|
CELL REPROGRAMMING AND THERAPEUTICS, LLC
|
|
Cellular MRI in Glioma and Radiation Necrosis
|
1R01CA122031-01A2
|
$247,950
|
$247,950
|
ALI, SYED
|
HENRY FORD HEALTH SYSTEM
|
|
DNA Methylation and GSTP1 Gene Regulation in Gliomas
|
5R01CA091438-06
|
$322,675
|
$322,675
|
Ali-Osman, Francis
|
DUKE UNIVERSITY
|
|
Novel Targeted Therapeutics for CNS Malignancies
|
5R01CA112519-02
|
$324,799
|
$162,400
|
Ali-Osman, Francis
|
DUKE UNIVERSITY
|
|
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas
|
7R01CA182076-05
|
$339,622
|
|
ALLEN, PETER
|
DUKE UNIVERSITY
|
|
Oncohistones: Role of Histone H3 Mutations in the Oncogenesis of Pediatric Cancers
|
5P01CA196539-04
|
$1,855,117
|
$1,855,117
|
ALLIS, CHARLES
|
ROCKEFELLER UNIVERSITY
|
|
Blood Flow MRI for Monitoring Glioma Angiogenesis
|
5R01CA115745-02
|
$333,543
|
$333,543
|
ALSOP, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-49
|
$2,645,581
|
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Par-4 Regulation and Function in Breast Cancer Dormancy and Recurrence
|
3R01CA208042-03S1
|
$223,893
|
|
ALVAREZ, JAMES
|
DUKE UNIVERSITY
|
|
Novel Markers for Disease Outcome in Breast Cancer
|
ZIA BC 010887
|
$399,760
|
|
Ambs, Stefan
|
CCR (NCI)
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$753,084
|
$37,654
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
|
1U01CA232382-01
|
$688,043
|
|
ANDERSON, ALEXANDER
|
H. LEE MOFFITT CANCER CTR & RES INST
|
Total relevant funding to Brain for this search: $178,224,282
|